SCHEMBL1407447

SCHEMBL1407447

COc1ccc(-c2c3cccc(F)c3nn2Cc2ccccc2F)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.47
NR1H3 Q13133 3/20 0.47
NR1I2 O75469 1/20 0.47
NR3C1 P04150 1/20 0.47
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MAPT P10636 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
P2RX7 Q99572 1/20 0.42
NPBWR1 P48145 2/20 0.41
ROCK2 O75116 1/20 0.40
KDM4E B2RXH2 3/20 0.40
TSHR P16473 2/20 0.40
LMNA P02545 1/20 0.40
RORC P51449 2/20 0.39
MDM2 Q00987 1/20 0.39
HSP90AA1 P07900 1/20 0.39
CYP1A1 P04798 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407762 0.92 NR1H2 (0.48) NR1H2NR1H3NR1I2NR3C1ALDH1A1
SCHEMBL1414643 0.92 NR1H2 (0.48) NR1H2NR1H3NR1I2NR3C1ALDH1A1
SCHEMBL1408297 0.91 NR1H2 (0.43) NR1H2NR1H3NR1I2NR3C1SMN1; SMN2
SCHEMBL1407455 0.89 NR1H2 (0.45) NR1H2NR1H3ALDH1A1KDM4EMDM2
SCHEMBL1408048 0.89 P2RX7 (0.48) NR1H2NR1H3NR1I2NR3C1ALDH1A1
SCHEMBL1407428 0.86 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1ALDH1A1
SCHEMBL1407316 0.85 P2RX7 (0.40) NR1H2NR1H3ALDH1A1MAPTP2RX7
SCHEMBL1407475 0.85 NR1H2 (0.46) NR1H2NR1H3ALDH1A1SMN1; SMN2KDM4E
SCHEMBL1407384 0.85 KMT2A (0.48) NR1H2NR1H3ALDH1A1MAPTRAB9A
SCHEMBL4030775 0.84 CYP1A1 (0.39) ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP claimed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP disclosed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885NR1I2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.